$PFE

Pfizer (PFE) and AbbVie (ABBV) are major U.S. drugmakers with diversified portfolios. Pfizer expects flat to slightly negative revenue growth in 2026 but aims for high single-digit CAGR from 2028. AbbVie anticipates 10.5% sales growth in 2026, driven by Skyrizi and Rinvoq. Both companies face patent expirations and competition. Analysts expect Pfizer's 2026 EPS to decrease 7.5%, while AbbVie's is projected to rise 40.5%.

Bristol Myers Squibb (BMY) and Pfizer (PFE) face patent expirations but differ in strategy. BMY focuses on oncology and immunology, while PFE pursues high-growth areas via acquisitions. BMY's FY 2025 revenue was $48.2B, net income $7.1B, and PFE's revenue was $62.6B, net income $7.8B. Both face legal and competitive risks, with BMY trading at a higher P/E.

Apple led The Irish Times' Top 1,000 rankings with €209.3bn revenue and €72bn profit. Microsoft, Meta, and Google followed. Eli Lilly entered the top 10. CRH was the largest indigenous company. Apple and Meta reduced Irish headcounts. Irish corporation taxes surged due to tech profits.

Pfizer and VNVC, a Vietnamese healthcare organization, exchanged cooperation documents to strengthen Vietnam's healthcare capacity. Pfizer will support VNVC in developing a vaccine manufacturing plant to meet international standards. The plant, with a first-phase investment of over VND 2.5 trillion, aims to produce 100-120 million vaccine doses annually starting 2029. Both companies expressed commitment to improving Vietnam's public health system and vaccination efforts.

Pfizer is integrating UHF RFID tags into medication labels during manufacturing, eliminating manual tagging in hospitals. Partnering with Bluesight, Pfizer aims to automate inventory management, reduce waste, and improve tracking. The technology uses open standards for interoperability with other RFID systems, enhancing hospital pharmacy workflows.

Pfizer (PFE) is refocusing its growth strategy, with new products offsetting declines in COVID-related revenue. The company highlighted vaccines, oncology, and chronic weight management as key growth areas. LORBRENA, a lung cancer treatment, generated $250 million internationally in the latest quarter, indicating a $1 billion annualized run rate. Pfizer also discussed expansion in China and the use of AI to enhance commercial productivity.

Health Canada confirmed a DNA fragment in Pfizer-BioNTech's Comirnaty COVID-19 vaccine, calling it inactive and below required limits. The department did not provide detailed records or dates requested by Conservative MP Glen Motz, citing over 3 billion doses administered globally with no safety signals.

Eli Lilly (LLY) reported Q2 2026 revenue of $22.97B, up 47.7% YoY, driven by Mounjaro and Zepbound. Pfizer (PFE) reported Q1 2026 revenue of $14.45B, up 5.4%, with growth in oncology and biosimilars. Lilly raised FY2026 guidance to $85.0B-$87.0B. Analysts debate Lilly's growth vs. Pfizer's yield and stability.

Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), and Bristol Myers Squibb (BMY) are highlighted for their dividend yields and strategies to mitigate patent expiration risks. JNJ raised its dividend to $1.34 per share, with strong cash flow and diversified revenue streams. PFE offers a 6.14% yield but faces significant patent expirations. MRK's dividend is backed by its oncology franchise, while BMY focuses on growth to offset legacy portfolio declines.

Pfizer is conducting a trial for a potential vaccine against Clostridioides difficile (C. diff) with 32,000 participants, including 19,000 in the UK. The vaccine aims to reduce severe infections caused by the superbug, which affects thousands annually and costs the NHS between £140 million and £330 million yearly. Results are expected in about three and a half years.